Veracyte (VCYT) Tops Q2 EPS by 2c, Amends Agreement with Sanofi's Genzyme
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Caterpillar names Derrick York to lead Resource Industries
- Intel shares drop on foundry risks, sector pressures
Veracyte (VCYT) PT, Estimates Bumped at Piper Jaffray Despite Q2 Rev Miss
August 14, 2014 6:57 AM EDTPiper Jaffray analyst William Quirk reiterated an Overweight rating while bumping estimates and his price target on Veracyte, Inc (NASDAQ: VCYT) following Q2 results and the related after hours sell-off on the revenue miss.
Quirk comments, "Veracyte reported a 71.2% yoy revenue increase... More



